期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 71, 期 18, 页码 2015-2040出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.12.068
关键词
coronary artery disease; geriatric cardiology; octogenarians
资金
- American Medical Association Foundation
- Gilead Sciences
- Sanofi
- GlaxoSmithKline
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Daiichi-Sankyo
- Janssen Pharmaceuticals
- Novartis Pharmaceutical Company
- Medtronic Foundation
- Pfizer
- U.S. Food and Drug Administration
- National Institutes of Health
- Boston Scientific
- Lilly
- Medtronic
- Merck
Coronary artery disease (CAD) is a major cause of morbidity and mortality in patients >= 80 years of age. Nonetheless, older patients have typically been under-represented in cardiovascular clinical trials. Understanding the pathophysiology, epidemiology, and optimal means of diagnosis and treatment of CAD in older adults is crucial to improving outcomes in this high-risk population. A patient-centered approach, taking into account health status, functional ability and frailty, cognitive skills, and patient preferences is essential when caring for older adults with CAD. The present systematic review focuses on the current knowledge base, gaps in understanding, and directions for future investigation pertaining to CAD in patients >= 80years of age. (C) 2018 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据